BS_CB6VK7PB
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- age_years
- 1.184
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.609
- CHOLESTEROL_HOMEOSTASIS+0.516
- INTERFERON_GAMMA_RESPONSE+0.510
- IL6_JAK_STAT3_SIGNALING+0.489
- ALLOGRAFT_REJECTION+0.405
- COMPLEMENT+0.371
- PROTEIN_SECRETION+0.353
- HEDGEHOG_SIGNALING+0.340
- ANDROGEN_RESPONSE+0.321
- TGF_BETA_SIGNALING+0.319
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.235
- SPERMATOGENESIS-0.192
- E2F_TARGETS-0.158
- G2M_CHECKPOINT-0.087
- KRAS_SIGNALING_DN-0.085
- APICAL_SURFACE-0.070
- UV_RESPONSE_UP-0.047
- ESTROGEN_RESPONSE_LATE-0.002
- NOTCH_SIGNALING-0.001
- UV_RESPONSE_DN+0.016
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_SXRS2P6T | low-grade glioma | — | 0.918 |
| 2 | BS_ZZMYDZJW | pilocytic astrocytoma | — | 0.908 |
| 3 | BS_CQEETJ66 | Schwannoma | — | 0.883 |
| 4 | 311D796C-BDD1-4C6B-9FD4-A053778AE1BB | — | — | 0.882 |
| 5 | DACCA07A-8F2C-40C5-B8AD-73805E408D85 | — | — | 0.881 |
| 6 | R250 | — | — | 0.881 |
| 7 | E5FB107A-9555-419F-84BF-2A59873104B9 | — | — | 0.880 |
| 8 | BS_8J3B6ZB6 | pilocytic astrocytoma | — | 0.877 |
| 9 | BS_MBSTWZA6 | pilocytic astrocytoma | — | 0.877 |
| 10 | BS_2KJ2YAZR | pilocytic astrocytoma | — | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.609 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.516 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.510 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.489 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.405 | Idelalisib | — uncovered |
| COMPLEMENT | 0.371 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.353 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.321 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.319 | Inavolisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.299 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.296 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.292 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.272 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.255 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.249 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.241 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.241 | Idelalisib | — uncovered |